FY2024 SEC EDGAR DEF 14A

Silence Therapeutics plc CEO pay ratio

The CEO earned $3.7M in FY2024 against median worker pay of $148,994 · Chemicals & Pharmaceuticals.

State
X0
Filing date
2025-05-16
Industry
Chemicals & Pharmaceuticals
Fiscal year
FY2024

Data updated August 2026

Subscribe to Silence Therapeutics plc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
25:1
Below Average (Scale: 0–1000:1)
CEO pay
$3.7M
Median worker
$148,994

Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.

Answer first

Silence Therapeutics plc reported a 25:1 CEO-to-worker pay ratio in FY2024 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.

Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Pay ratio
25:1
FY2024 disclosed
CEO total
$3.7M
Summary Compensation Table total
Median worker
$148,994
Dodd-Frank median employee

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2024

A component-level pay breakdown is not reported in Silence Therapeutics plc's structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
25:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$3.7M
Companies in Industry
168
vs. Industry Median
Below

Silence Therapeutics plc: MODEST · MID$ pay ratio

Silence Therapeutics plc disclosed 25:1 CEO-to-worker pay and $3.7M CEO total in FY2024. the CEO earned 25× the median employee ($148,994) in FY2024.

Median employee $148,994 (ELITE-MED); MODEST · MID$ stamps put about 25 median-wage years per CEO year.

CEO Total Pay

$3.7M

FY2024 Summary Compensation, below median

Pay Ratio

25:1

Below typical

What FY2024 shows for Silence Therapeutics plc

Silence Therapeutics plc disclosed 25:1 CEO-to-worker pay and $3.7M CEO total in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Silence Therapeutics plc's $3.7M CEO total is at or below the $7.9M industry median CEO pay.

Silence Therapeutics plc stamps MODEST · MID$ · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2024

Total Compensation
$3.7M
Median Employee Pay
$148,994
Pay Ratio
25:1
Filing Date
2025-05-16

Company Info

CIK
1479615
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
X0
SEC EDGAR DEF 14A for CIK 1479615, FY2024. Informational only, not investment advice. Verify on EDGAR.

Read with Silence Therapeutics plc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · MID$ · ELITE-MED.

Data sourced from SEC EDGAR DEF 14A for Silence Therapeutics plc (CIK 1479615), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.